Last reviewed · How we verify
NCT07082751
Prognostic Model for MASLD Related Cirrhosis
trial testing Lifestyle Guidance in Metabolic Dysfunction Associated Steatotic Liver Disease in 228 participants. Not yet recruiting.
30 June 2030
Quick facts
| Lead sponsor | Beijing Friendship Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 228 |
| Start date | 13 August 2025 |
| Primary completion | 30 June 2030 |
| Estimated completion | 30 June 2030 |
| Sites | 9 locations across China |
Drugs / interventions tested
- Lifestyle Guidance
Conditions studied
- Metabolic Dysfunction Associated Steatotic Liver Disease — all drugs for Metabolic Dysfunction Associated Steatotic Liver Disease →
- Compensated Cirrhosis — all drugs for Compensated Cirrhosis →
Sponsor
Beijing Friendship Hospital
Who can join
Adults 18 to 80, any sex, with Metabolic Dysfunction Associated Steatotic Liver Disease or Compensated Cirrhosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study enrolled 228 patients with MASLD-related cirrhosis confirmed by histopathology or clinical diagnosis. Follow-up was conducted every 3-6 months. The primary endpoint was cumulative incidence of liver-related events (including decompensation events, hepatocellular carcinoma, liver transplantation, and liver-related mortality) and all-cause mortality. Secondary endpoints included cumulative incidence of metabolic events and changes in non-invasive fibrosis markers.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07082751
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metabolic Dysfunction Associated Steatotic Liver Disease
Currently open trials in the same condition.
- NCT06935994 — Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease · Phase 2 · recruiting
- NCT06854185 — Feasibility of the Paso Program for Patients With Metabolic Dysfunction Associated Steatotic Liver Disease · NA · active not recruiting
- NCT06490432 — Pattern of Cardiac Arrhythmia in Patients With MASLD · recruiting
Other Beijing Friendship Hospital trials
Trials by the same sponsor.
- NCT07453862 — Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety · Phase 1 · recruiting
- NCT07397442 — Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07393048 — Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant The · recruiting
- NCT07441850 — Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy · NA · recruiting
- NCT07369739 — Golidocitinib Combined With Selinexor for CAEBVD · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07082751 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Friendship Hospital
- Last refreshed: 24 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07082751.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing